Elixir Medical will host a live case demonstration of its DESolve 100 Novolimus Eluting Bioresorbable Coronary Scaffold System at EuroPCR in Paris on 20 May 2014.

DESolve 100 is claimed to be the world’s first fully bioresorbable scaffold with a thinner strut profile of 100µm, which will degrade within one year, returning the patients’ coronary vessel finally to its normal de novo state.

The CE-Marked DESolve 100 is expected to make scaffolds more user-friendly and help cardiologists meet the needs of the patients.

During the conference, Elixir will also present additional data on its drug eluting stent platforms apart from an update on trials for DESolve family of scaffolds.

EuroPCR is the official annual meeting of the European Association for Percutaneous Cardiovascular Interventions.